PloS one · 2025
Developing a multivariable prediction model to support personalized selection among five major empirically-supported treatments for adult depression. Study protocol of a systematic review and individual participant data network meta-analysis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Driessen Ellen, Efthimiou Orestis, Wienicke Frederik J, Breunese Jasmijn, Cuijpers Pim, Debray Thomas P A, Fisher David J, Fokkema Marjolein, Furukawa Toshiaki A, Hollon Steven D, Mehta Anuj H P, Riley Richard D, Schmidt Madison R, Twisk Jos W R, Cohen Zachary D
Аннотация
BACKGROUND: Various treatments are recommended as first-line options in practice guidelines for depression, but it is unclear which is most efficacious for a given person. Accurate individualized predictions of relative treatment effects are needed to optimize treatment recommendations for depression and reduce this disorder's vast personal and societal costs.
AIMS: We describe the protocol for a systematic review and individual participant data (IPD) network meta-analysis (NMA) to inform personalized treatment selection among five major empirically-supported depression treatments.
METHOD: We will use the METASPY database to identify randomized clinical trials that compare two or more of five treatments for adult depression: antidepressant medication, cognitive therapy, behavioral activation, interpersonal psychotherapy, and psychodynamic therapy. We will request IPD from identified studies. We will conduct an IPD-NMA and develop a multivariable prediction model that estimates individualized relative treatment effects from demographic, clinical, and psychological participant characteristics. Depressive symptom level at treatment completion will constitute the primary outcome. We will evaluate this model using a range of measures for discrimination and calibration, and examine its potential generalizability using internal-external cross-validation.
CONCLUSIONS: We describe a state-of-the-art method to predict personalized treatment effects based on IPD from multiple trials. The resulting prediction model will need prospective evaluation in mental health care for its potential to inform shared decision-making. This study will result in a unique database of IPD from randomized clinical trials around the world covering five widely used depression treatments, available for future research.
AIMS: We describe the protocol for a systematic review and individual participant data (IPD) network meta-analysis (NMA) to inform personalized treatment selection among five major empirically-supported depression treatments.
METHOD: We will use the METASPY database to identify randomized clinical trials that compare two or more of five treatments for adult depression: antidepressant medication, cognitive therapy, behavioral activation, interpersonal psychotherapy, and psychodynamic therapy. We will request IPD from identified studies. We will conduct an IPD-NMA and develop a multivariable prediction model that estimates individualized relative treatment effects from demographic, clinical, and psychological participant characteristics. Depressive symptom level at treatment completion will constitute the primary outcome. We will evaluate this model using a range of measures for discrimination and calibration, and examine its potential generalizability using internal-external cross-validation.
CONCLUSIONS: We describe a state-of-the-art method to predict personalized treatment effects based on IPD from multiple trials. The resulting prediction model will need prospective evaluation in mental health care for its potential to inform shared decision-making. This study will result in a unique database of IPD from randomized clinical trials around the world covering five widely used depression treatments, available for future research.